The Royal Marsden, a world-leading cancer centre that specialises in diagnosis, treatment, care and research, has installed two hybrid PET-CT systems from Siemens Healthcare to support the need for increased capacity.
The fully integrated Biograph™ mCT imaging systems will enable the hospital to meet increased demand for its clinical services. The hospital will also be able to support effective throughput of patients, alongside conducting its radiopharmaceutical research and novel tracer development in partnership with the Institute of Cancer Research. The mCT systems will be used primarily for 64 and 128-slice full and half body imaging with reproducible quantification enabling clinicians to detect, characterise and monitor cancer lesions with greater precision.
The hospital is also making use of the Biograph mCT’s TrueV option, enabling patients to be placed in fewer positions, while also benefitting from lower dose rates or improved scan times. The systems have been installed within a newly extended PET-CT suite designed to accommodate innovative technology and create a more comfortable clinical environment. The facility features sufficient clinical space to accommodate routine work as well as research and also provides 6 individual uptake rooms to ensure maximum utilisation of the scanners.
“We chose the Biograph mCT from Siemens Healthcare following a thorough appraisal of all available systems on the market,” explains Bernadette Cronin, Deputy Director for Clinical Services at The Royal Marsden NHS Foundation Trust. “It is a fantastic imaging resource for both our clinical and research teams and due to its dual functionality the mCT can be used as a molecular CT or standalone CT scanner when required. Our technologists also rate the user interface highly, which is intuitive and requires minimal staff training.” “The Royal Marsden is renowned for leading the way when it comes to cancer care and research,” comments Malcolm Pickering, Regional Sales Manager at Siemens Healthcare.
“The innovative hybrid system integrates the high performance of both HD•PET and CT modalities into a single compact system. It will ensure the new PET-CT suite at The Royal Marsden remains at the cutting edge of oncology diagnosis and research, while providing the best possible facilities for patients.”
Latest from Healthcare Technology Magazine News
- Global Healthcare IT Market Will Grow At A CAGR Of 5.7% to 2018
- BRHC Supports Centralisation Of Specialist Paediatric Services With Three New C-arms
- Procura Group of Companies Leads US Market
- CellTrak™ Achieves Major Milestone in roll-out of Latest Platform
- Introducing First-of-a-Kind PhysIQ Predictive Analytic Technology for Proactive Health Monitoring
- CareCloud Continues to Expand Market Footprint, Product Innovation, and Infrastructure for Growth in Second Quarter of 2014
- Mark VanderWerf Elected Chairman American Telemedicine Association’s Industry Council
- GlobalMed Announces New Alliance for Transforming Healthcare Delivery In The Middle East Through Telemedicine
- Secure Mobile Communication Market in Healthcare Industry
- The Promise of Integrated Healthcare: Health Information Systems